September 2021: The FDA granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals, Inc.) for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 20 insertio..
August 2021: The FDA granted accelerated approval to sotorasib (LumakrasTM, Amgen, Inc.), a RAS GTPase family inhibitor, for adult patients with KRAS G12C mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) w..
August 2021: Lorlatinib (Lorbrena, Pfizer Inc.) received regular FDA approval for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive, as determined by an FDA-app..
August 2021: Lorlatinib (Lorbrena, Pfizer Inc.) received regular FDA approval for patients with metastatic non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive, as determined by an FDA-app..
ເດືອນສິງຫາ 2021: FDA ໄດ້ອະນຸມັດ cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc. ) ສໍາລັບການປິ່ນປົວແຖວທໍາອິດຂອງຄົນເຈັບທີ່ເປັນມະເຮັງປອດຈຸລັງທີ່ບໍ່ແມ່ນຈຸລັງຂັ້ນສູງ (NSCLC) (ຂັ້ນທ້ອງຖິ່ນທີ່ບໍ່ແມ່ນຜູ້ສະforັກຮັບການຜ່າຕັດ).
ວັນທີ 20 ເດືອນສິງຫາປີ 2021: ເມື່ອບໍ່ດົນມານີ້ໃນເດືອນພຶດສະພາ, 2021 Lumakras (sotorasib) ໄດ້ຮັບການອະນຸມັດຈາກອົງການອາຫານແລະຢາຂອງສະຫະລັດອາເມລິກາວ່າເປັນການປິ່ນປົວຄັ້ງທໍາອິດສໍາລັບຄົນເຈັບຜູ້ໃຫຍ່ທີ່ເປັນມະເຮັງປອດທີ່ບໍ່ແມ່ນຈຸລັງຂະ ໜາດ ນ້ອຍທີ່ໄດ້ຜ່ານຢ່າງ ໜ້ອຍ ໜຶ່ງ ລະບົບກ່ອນ ໜ້າ ນີ້.
ວັນທີ 7 ເດືອນກໍລະກົດປີ 2021: ການສູບຢາເປັນສາເຫດຫຼັກຂອງມະເລັງປອດ, ກວມເອົາຫຼາຍກວ່າ 80% ຂອງຜູ້ເສຍຊີວິດຈາກພະຍາດທັງ ໝົດ. ເຖິງຢ່າງໃດກໍ່ຕາມຄົນທີ່ບໍ່ສູບຢາຍັງມີຄວາມສ່ຽງຕໍ່ການເປັນມະເລັງປອດ. ອີງຕາມການສຶກສາໃຫມ່, arou ..
What to do about drug resistance of non-small cell lung cancer targeted drugs, you want to know hereLung cancer is the cancer with the highest morbidity and mortality in China. About 1.6 million people die of this disease each yea..
Lung cancer immunotherapy, lung cancer immunotherapy, lung cancer PD-1 treatment, and lung cancer PD-L1 treatment are all you want to know. In the past two years, immune checkpoint inhibitors have undoubtedly been one of the most..
Dong-Wan Kim scholars from the Seoul National University Hospital in South Korea will give an oral report on the special meeting of metastatic non-small cell lung cancer at the 52nd Annual Meeting of the American Society of Oncolo..